Sunday, September 25, 2016 11:36:25 AM
As long as partial halt for additional patient screening is concerned, it may have nothing to do with the screening per se in the first place; otherwise it would be solved in due time.
Just want to add to your excellent summary:
Public traded companies, big or small, do those independent internal investigations into their own affairs all the time, due to either internal or external pressure.
Almost all would not report the findings publicly and instead they would make appropriate (correct) actions either due to the requirements of compliance or otherwise.
In the case of nwbo, I think the process is still on going, but the company has actually revealed some investigating results via SEC filing:
1) the company has hired additional personnel to improve on its financial affairs reporting, including 10Q, 10K, etc, to further separate duties from LP in this front;
2) Yes, the MFN clause has been removed to align LP's interests with those of investors;
3) the company has hired additional independent directors to strength the board;
4) the company has paid off all its money owing to Four M in accordance with their patent-in-trust agreement so now the company is in full control of its patent portfolio.
As a matter of fact, all the outstanding issues detected by auditors have been all solved except one item (what specifically I don't recall at this time).
So the company has moved forward positively toward a company with good governance.
I guess if LP has no confidence in the future of the company, it would be no reason for she to have implemented the above.
Yes, the company has strongly suggested the L trial has been moving toward completion for months now since Q2 report. It is a strong possibility that the results of L trial may be available in the near future.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
